Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bioventus (BVS) EBT Margin (2020 - 2026)

Bioventus filings provide 6 years of EBT Margin readings, the most recent being 8.96% for Q4 2025.

  • On a quarterly basis, EBT Margin rose 899.0% to 8.96% in Q4 2025 year-over-year; TTM through Dec 2025 was 4.53%, a 1366.0% increase, with the full-year FY2025 number at 4.53%, up 1366.0% from a year prior.
  • EBT Margin hit 8.96% in Q4 2025 for Bioventus, up from 3.37% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 29.9% in Q2 2021 to a low of 101.47% in Q4 2022.
  • Median EBT Margin over the past 5 years was 4.01% (2024), compared with a mean of 12.56%.
  • Biggest five-year swings in EBT Margin: tumbled -9858bps in 2022 and later skyrocketed 9469bps in 2023.
  • Bioventus' EBT Margin stood at 2.11% in 2021, then crashed by -1123bps to 25.78% in 2022, then soared by 76bps to 6.21% in 2023, then surged by 99bps to 0.03% in 2024, then surged by 26065bps to 8.96% in 2025.
  • The last three reported values for EBT Margin were 8.96% (Q4 2025), 3.37% (Q3 2025), and 6.98% (Q2 2025) per Business Quant data.